MA28901B1 - Methode de traitement de cancers - Google Patents

Methode de traitement de cancers

Info

Publication number
MA28901B1
MA28901B1 MA29554A MA29554A MA28901B1 MA 28901 B1 MA28901 B1 MA 28901B1 MA 29554 A MA29554 A MA 29554A MA 29554 A MA29554 A MA 29554A MA 28901 B1 MA28901 B1 MA 28901B1
Authority
MA
Morocco
Prior art keywords
treating cancers
cancers
treating
Prior art date
Application number
MA29554A
Other languages
English (en)
Inventor
Mark S Berger
Tona Morgan Gilmer
Arundathy Nirmalini Pandite
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of MA28901B1 publication Critical patent/MA28901B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA29554A 2004-06-04 2006-12-25 Methode de traitement de cancers MA28901B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57733704P 2004-06-04 2004-06-04

Publications (1)

Publication Number Publication Date
MA28901B1 true MA28901B1 (fr) 2007-10-01

Family

ID=35503649

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29554A MA28901B1 (fr) 2004-06-04 2006-12-25 Methode de traitement de cancers

Country Status (14)

Country Link
US (1) US20090317383A1 (fr)
EP (1) EP1765344A4 (fr)
JP (1) JP2008501708A (fr)
KR (1) KR20070034536A (fr)
CN (2) CN1984656B (fr)
AU (2) AU2005251769B2 (fr)
BR (1) BRPI0511765A (fr)
CA (1) CA2569139A1 (fr)
IL (1) IL179323A0 (fr)
MA (1) MA28901B1 (fr)
MX (1) MXPA06013952A (fr)
NO (1) NO20066079L (fr)
RU (2) RU2361589C2 (fr)
WO (1) WO2005120512A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080306097A1 (en) * 2004-12-17 2008-12-11 Smithkline Beecham (Cork) Limited Cancer Treatment Method
WO2007143483A2 (fr) * 2006-06-01 2007-12-13 Smithkline Beecham Corporation Procédé de traitement du cancer
CA2661223A1 (fr) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. Derives de 4-aminoquinazoline et leurs procedes d'utilisation
AU2007307489A1 (en) 2006-10-06 2008-04-17 Takeda Pharmaceutical Company Limited Combination drug
US20100069411A1 (en) * 2006-11-28 2010-03-18 Smithkline Beecham (Cork) Ltd. Cancer treatment method
CA2675366A1 (fr) * 2007-01-18 2008-07-24 University Of Southern California Polymorphismes geniques predictifs d'une bitherapie a base de tki
PE20091624A1 (es) 2008-03-03 2009-11-19 Takeda Pharmaceutical Farmaco combinado a base de un inhibidor de her2 derivado de pirrolopirimidina o pirazolopirimidina
WO2009137714A2 (fr) 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Formes de ditosylate de lapatinib et procédés pour leur préparation
EP3620154A1 (fr) 2009-02-06 2020-03-11 University Of Southern California Compositions thérapeutiques comprenant des monoterpènes
US8568968B2 (en) 2009-04-13 2013-10-29 University Of Southern California EGFR polymorphisms predict gender-related treatment
US20140302050A1 (en) * 2011-11-09 2014-10-09 Albert Einstein College Of Medicine Of Yeshiva University Targeting an amphiregulin-derived cell surface neo-epitope

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
JP2002500667A (ja) * 1997-05-27 2002-01-08 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
DE60124387T2 (de) * 2000-02-28 2007-10-11 Pfizer Enterprises Sarl. Synergistische pharmazeutische Zusammensetzungen zur Behandlung von kolorektalem Krebs
CA2413134C (fr) * 2000-06-30 2010-05-11 Glaxo Group Limited Composes ditosylates de quinazoline
US7141576B2 (en) * 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
WO2005011607A2 (fr) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Traitement des cancers exprimant p95erbb2
US8211030B2 (en) * 2009-03-26 2012-07-03 The General Electric Company NIBP target inflation pressure automation using derived SPO2 signals

Also Published As

Publication number Publication date
CN101564535A (zh) 2009-10-28
BRPI0511765A (pt) 2008-01-08
CN1984656B (zh) 2010-05-26
US20090317383A1 (en) 2009-12-24
KR20070034536A (ko) 2007-03-28
WO2005120512A2 (fr) 2005-12-22
CN1984656A (zh) 2007-06-20
AU2005251769A1 (en) 2005-12-22
RU2008150250A (ru) 2010-06-27
WO2005120512A3 (fr) 2006-04-27
AU2005251769B2 (en) 2008-10-02
IL179323A0 (en) 2007-05-15
RU2361589C2 (ru) 2009-07-20
CA2569139A1 (fr) 2005-12-22
RU2006142418A (ru) 2008-07-20
AU2008229859A1 (en) 2008-10-30
MXPA06013952A (es) 2007-02-08
NO20066079L (no) 2007-01-12
EP1765344A2 (fr) 2007-03-28
EP1765344A4 (fr) 2009-12-02
JP2008501708A (ja) 2008-01-24

Similar Documents

Publication Publication Date Title
FR21C1063I1 (fr) Traitement combiné de tumeurs exprimant la cd38
EP1732650A4 (fr) Composition et methode de traitement du cancer
EP1667680A4 (fr) Methodes combinees de traitement du cancer
EP1830876A4 (fr) Traitement de metastases cutanees
EP1636359A4 (fr) Methodes de traitement de la douleur
EP1575580A4 (fr) Methodes de traitement de cancers
EP1755584A4 (fr) Traitement de la myopie
EP1991230A4 (fr) Méthodes de traitement du cancer
EP1677816A4 (fr) Methode de traitement
EP1830869A4 (fr) Procede de traitement ou prophylaxie
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
EP1968582A4 (fr) Traitement du lymphome t cutane
EP1982660A4 (fr) Endoscope de traitement
DE602005012489D1 (de) Verfahren zur Abwasserbehandlung
EP1613308A4 (fr) Procedes de traitement du cancer
EP1680073A4 (fr) Composes et methode de traitement du cancer
ATE430187T1 (de) Zusammensetzungen zur wäschebehandlung
EP1838330A4 (fr) Traitement de cancers solides
EP1838714A4 (fr) Procedes de traitement de la douleur
EP1858587A4 (fr) Appareil de traitement esthetique
EP1833511A4 (fr) Methode de traitement du cancer du cerveau
EP1677805A4 (fr) Traitement du cancer du pancreas
EP1937892A4 (fr) Methode de traitement de materiaux lignocellulosiques
EP2219452A4 (fr) Procédés de traitement de la sclérodermie
EP2068911A4 (fr) Procédés de traitement du cancer